Summary
Global Markets Direct’s, ‘Polycystic Kidney Disease - Pipeline Review, H1 2016’, provides an overview of the Polycystic Kidney Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease
- The report reviews pipeline therapeutics for Polycystic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Polycystic Kidney Disease therapeutics and enlists all their major and minor projects
- The report assesses Polycystic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3SBio Inc.
Angion Biomedica Corp.
DiscoveryBiomed, Inc.
Endocyte, Inc.
IC-MedTech, Inc.
Ipsen S.A.
Kadmon Corporation, LLC
Metabolic Solutions Development Company, LLC
NovaTarg Therapeutics, Inc
Otsuka Holdings Co., Ltd.
Synta Pharmaceuticals Corp.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Polycystic Kidney Disease Overview 9
Therapeutics Development 10
Pipeline Products for Polycystic Kidney Disease - Overview 10
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11
Polycystic Kidney Disease - Therapeutics under Development by Companies 12
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 13
Polycystic Kidney Disease - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Polycystic Kidney Disease - Products under Development by Companies 17
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 18
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 19
3SBio Inc. 19
Angion Biomedica Corp. 20
DiscoveryBiomed, Inc. 21
Endocyte, Inc. 22
IC-MedTech, Inc. 23
Ipsen S.A. 24
Kadmon Corporation, LLC 25
Metabolic Solutions Development Company, LLC 26
NovaTarg Therapeutics, Inc 27
Otsuka Holdings Co., Ltd. 28
Synta Pharmaceuticals Corp. 29
Polycystic Kidney Disease - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(ascorbic acid + menadione) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ANG-3070 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CIM-2 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DBM-43H11 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DJ-5 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drugs for Polycystic Kidney Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
EC-0371 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JP-153 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lanreotide acetate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MSDC-0160 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MSDC-0602 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
oxypurinol - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pyrimethamine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
STA-2842 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
tesevatinib tosylate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
tolvaptan - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Polycystic Kidney Disease - Recent Pipeline Updates 67
Polycystic Kidney Disease - Dormant Projects 77
Polycystic Kidney Disease - Discontinued Products 78
Polycystic Kidney Disease - Product Development Milestones 79
Featured News & Press Releases 79
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 79
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 80
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 80
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 81
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 82
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 83
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide 84
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 85
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 86
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88
List of Tables
Number of Products under Development for Polycystic Kidney Disease, H1 2016 10
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Polycystic Kidney Disease - Pipeline by 3SBio Inc., H1 2016 19
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H1 2016 20
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H1 2016 21
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H1 2016 22
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H1 2016 23
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H1 2016 24
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H1 2016 25
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016 26
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 27
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 28
Polycystic Kidney Disease - Pipeline by Synta Pharmaceuticals Corp., H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Assessment by Combination Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Polycystic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2016 67
Polycystic Kidney Disease - Dormant Projects, H1 2016 77
Polycystic Kidney Disease - Discontinued Products, H1 2016 78
List of Figures
Number of Products under Development for Polycystic Kidney Disease, H1 2016 10
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Top 10 Targets, H1 2016 32
Number of Products by Stage and Top 10 Targets, H1 2016 32
Number of Products by Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Molecule Types, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 38
